文献速递临床试验与 GCP真实世界研究与卫生经济流行病学与生物统计

闪速血糖监测能否改善原住民与托雷斯海峡岛民2型糖尿病患者的血糖管理?一项随机对照试验的研究方案

Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2024-07-19

本研究为在澳大利亚原住民与托雷斯海峡岛民2型糖尿病患者中开展的非盲、平行分组、两臂、个体随机对照试验,比较持续血糖监测(CGM)与自我血糖监测(SMBG)对糖化血红蛋白(HbA1c)、血糖达标、低血糖事件及成本效果的影响,计划纳入350例,干预6个月,主要结局为HbA1c从基线至6个月的变化。

要点

  • 研究对象为接受注射治疗且HbA1c≥7.5%的原住民与托雷斯海峡岛民2型糖尿病成人。
  • 350例按1:1随机分为CGM组与SMBG组,干预6个月,主要结局为HbA1c变化。
  • 试验在澳大利亚原住民社区控制组织、原住民医疗服务机构、初级保健中心及三级医院开展。

核心结论

  • 该试验将评估CGM与SMBG相比对澳大利亚原住民与托雷斯海峡岛民2型糖尿病患者HbA1c的影响。
  • 作者认为该试验可能对改善糖尿病管理具有长期益处,并为该人群CGM的资助提供证据。

研究设计与样本

  • 非盲、平行分组、两臂、个体随机对照试验(ACTRN12621000753853)。
  • 纳入接受注射治疗且HbA1c≥7.5%的原住民与托雷斯海峡岛民2型糖尿病成人,共350例,按1:1随机分为CGM组或SMBG组,干预6个月。
  • 试验地点包括澳大利亚城市、农村、区域和偏远地区的原住民社区控制组织、原住民医疗服务机构、初级保健中心和三级医院。

主要发现

  • 主要结局为HbA1c从基线至6个月的变化。
  • 次要结局包括CGM衍生指标、低血糖事件频率、健康相关生活质量,以及CGM相较SMBG的每获得一个质量调整生命年的增量成本。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aboriginal and Torres Strait Islander peoples are disproportionately impacted by type 2 diabetes. Continuous glucose monitoring (CGM) technology (such as Abbott Freestyle Libre 2, previously referred to as Flash Glucose Monitoring) offers real-time glucose monitoring that is convenient and easy to use compared to self-monitoring of blood glucose (SMBG). However, this technology's use is neither widespread nor subsidised for Aboriginal and Torres Strait Islander peoples with type 2 diabetes. Building on existing collaborations with a national network of Aboriginal and Torres Strait Islander communities, this randomised controlled trial aims to assess the effect of CGM compared to SMBG on (i) haemoglobin A1c (HbA1c), (ii) achieving blood glucose targets, (iii) reducing hypoglycaemic episodes and (iv) cost-effective healthcare in an Aboriginal and Torres Strait Islander people health setting. METHODS: This is a non-masked, parallel-group, two-arm, individually randomised, controlled trial (ACTRN12621000753853). Aboriginal and Torres Strait Islander adults with type 2 diabetes on injectable therapy and HbA1c ≥ 7.5% (n = 350) will be randomised (1:1) to CGM or SMBG for 6 months. The primary outcome is change in HbA1c level from baseline to 6 months. Secondary outcomes include (i) CGM-derived metrics, (ii) frequency of hypoglycaemic episodes, (iii) health-related quality of life and (iv) incremental cost per quality-adjusted life year gained associated with the CGM compared to SMBG. Clinical trial sites include Aboriginal Community Controlled Organisations, Aboriginal Medical Services, primary care centres and tertiary hospitals across urban, rural, regional and remote Australia. DISCUSSION: The trial will assess the effect of CGM compared to SMBG on HbA1c for Aboriginal and Torres Strait Islander people with type 2 diabetes in Australia. This trial could have long-term benefits in improving diabetes management and providing evidence for funding of CGM in this population. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry ACTRN12621000753853. Registered on 15th June 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hachem M, Hearn T, Kelly R, et al. Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trial. Trials. 2024. PMID: 39030640. doi:10.1186/s13063-024-08267-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。